188260
Sanigen Co. Ltd, a food sanitation and safety specialist, develops and services solutions for safe food manufacturing, distribution, and sales in Korea and internationally. The company offers PCR detection and nucleic acid extraction kits; bag, diluent, beam template, macroswab, and squeeze products; pathogen detection NGS panel kits; and hand sanitizers, vomit clean up kits, and pure systems. It… Read more
188260 (188260) - Net Assets
Latest net assets as of March 2025: ₩9.24 Billion KRW
Based on the latest financial reports, 188260 (188260) has net assets worth ₩9.24 Billion KRW as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩16.07 Billion) and total liabilities (₩6.83 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩9.24 Billion |
| % of Total Assets | 57.49% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
188260 - Net Assets Trend (2022–2024)
This chart illustrates how 188260's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 188260 (2022–2024)
The table below shows the annual net assets of 188260 from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩10.20 Billion | -26.47% |
| 2023-12-31 | ₩13.87 Billion | +207.30% |
| 2022-12-31 | ₩-12.92 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to 188260's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1402665434000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩3.61 Billion | 35.45% |
| Other Components | ₩38.43 Billion | 376.92% |
| Total Equity | ₩10.20 Billion | 100.00% |
188260 Competitors by Market Cap
The table below lists competitors of 188260 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Boswell J G Co
PINK:BWEL
|
$4.91 Million |
|
Royal Helium Ltd
OTCQB:RHCCF
|
$4.91 Million |
|
Verb Technology Company Inc
NASDAQ:VERB
|
$4.91 Million |
|
HPP Holdings Bhd
KLSE:0228
|
$4.91 Million |
|
Bermas SA
RO:BRM
|
$4.90 Million |
|
VisDynamics Holdings Bhd
KLSE:0120
|
$4.90 Million |
|
Pixon Technologies Corporation
TWO:5248
|
$4.90 Million |
|
Soder Sportfiske AB
ST:SODER
|
$4.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 188260's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,867,188,460 to 10,196,017,800, a change of -3,671,170,660 (-26.5%).
- Net loss of 5,069,856,020 reduced equity.
- Other factors increased equity by 1,398,685,360.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-5.07 Billion | -49.72% |
| Other Changes | ₩1.40 Billion | +13.72% |
| Total Change | ₩- | -26.47% |
Book Value vs Market Value Analysis
This analysis compares 188260's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩-1934.10 | ₩1688.00 | x |
| 2023-12-31 | ₩2094.06 | ₩1688.00 | x |
| 2024-12-31 | ₩1436.40 | ₩1688.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 188260 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -21.12%
- • Asset Turnover: 1.44x
- • Equity Multiplier: 1.63x
- Recent ROE (-49.72%) is below the historical average (-37.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | -15.19% | 1.71x | 0.00x | ₩-2.77 Billion |
| 2023 | -63.28% | -39.41% | 1.04x | 1.55x | ₩-10.16 Billion |
| 2024 | -49.72% | -21.12% | 1.44x | 1.63x | ₩-6.09 Billion |
Industry Comparison
This section compares 188260's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 188260 (188260) | ₩9.24 Billion | 0.00% | 0.74x | $4.90 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |